A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

NCT07153796 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

DRUG: Blinatumomab
DRUG: Mini-CVD
DRUG: MTX/ARA-C

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]